Sectors
SLNO
Soleno Therapeutics, Inc.
39.49
2 x 39.42
2 x 39.73
bid
ask
+
2.50
6.76%
2 @ 04:00 PM
39.65 +0.16 (0.41%)
Ytd -14.71%
1y -46.40%
36.00
day range
40.08
30.05
52 week range
88.49
Open 36.25 Prev Close 36.99 Low 36.00 High 40.08 Mkt Cap 2.12B
Vol 3.56M Avg Vol 1.69M EPS 0.39 P/E 101.26 Forward P/E -17.40
Beta -3.03 Short Ratio 5.81 Inst. Own 129.54% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 05-06 50-d Avg 37.99 200-d Avg 57.31 1yr Est 105.15
Earning
Date For Estimate Reported Surprise surprise %
2026-05-06 2026-03 0.73 N/A N/A N/A
2026-02-25 2025-12 0.64 0.8 0.16 25.00%
2025-11-04 2025-09 0 0.47 N/A N/A
2025-08-06 2025-06 0 N/A 0.44 83.02%
2025-05-07 2025-03 0 N/A 0.19 16.67%
2025-02-27 2024-12 0 N/A -0.64 -101.59%
Upgrade / Downgrade
Date Firm Action From To
2026-03-18 Oppenheimer Upgrade Outperform Outperform
2026-03-04 HC Wainwright & Co. Upgrade Buy Buy
2026-02-27 Wells Fargo Upgrade Overweight Overweight
2026-02-26 TD Cowen Upgrade Buy Buy
2026-01-20 Wells Fargo Upgrade Overweight Overweight
2026-01-20 HC Wainwright & Co. Upgrade Buy Buy
Profile
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Insider Holder
Date Name Relation Quantity Description
2026-01-20 ANISH BHATNAGAR Chief Executive Officer 583.66K Stock Award(Grant)
2026-03-01 FULK JENNIFER Chief Financial Officer 39.20K Conversion of Exercise of derivative security
2026-01-20 HIRANO PATRICIA C Officer 22.70K Stock Award(Grant)
2026-03-26 HUANG MICHAEL F Officer 39.82K Sale
2026-01-20 JOSHI MANHER Officer 20.17K Stock Award(Grant)
2026-01-20 MACKANESS JAMES H Chief Financial Officer 131.76K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 FMR, LLC 8.08M 319.05M 15.65%
2025-12-30 Janus Henderson Group PLC 7.18M 283.47M 13.90%
2025-12-30 Blackrock Inc. 3.87M 152.89M 7.50%
2025-12-30 Wellington Management Group, LLP 3.32M 131.22M 6.44%
2025-12-30 Price (T.Rowe) Associates Inc 3.32M 131.06M 6.43%
2025-12-30 Vanguard Group Inc 3.06M 120.85M 5.93%
Fund Ownership
Report Date Organization Position Value Percentage
2026-01-30 VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund 2.42M 95.46M 4.68%
2026-02-27 Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 1.95M 76.85M 3.77%
2026-01-30 SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF 1.65M 65.24M 3.20%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 1.63M 64.31M 3.15%
2025-12-30 T. Rowe Price All-Cap Opportunities Fd., Inc.-T. Rowe Price All-Cap Op 1.32M 52.14M 2.56%
2026-01-30 iShares Trust-iShares Russell 2000 ETF 1.11M 44.01M 2.16%
Split
Split Date
1 : 15 2022-08-26
1 : 5 2017-10-06